



ASX Announcement

Termination of Supply Agreement

Sydney, Australia, 2 May 2022: Imugene (ASX: IMU) today announced termination of its supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA.

Imugene is continuing with its clinical trial to evaluate the safety and efficacy with the use of Imugene's HER-Vaxx, a B-cell activating immunotherapy in patients with HER-2 positive gastric cancer in combination with anti-PD-1 therapy.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer

info@imugene.com

Investor Enquiries

investor@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

About Gastric and Gastro-esophageal Cancer

Treatment of gastric or gastro-esophageal cancer remains an unmet need for HER-2 positive patients after they have failed trastuzumab. Immune checkpoint inhibitors have been successfully introduced to metastatic gastric cancer. Combining HER-Vaxx with immune checkpoint inhibitors may improve treatment outcomes for patients with this difficult to treat cancer.

About HER-Vaxx

Imugene's HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and



pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies and in Phase 1 and 2 studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia